Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin Hydrochloride Dicarboxylate Sustained-release Tablets (Ⅲ) in T2DM with CHD
NCT06932874Phase 4Recruiting
- Sponsor
- National Center for Cardiovascular Disease
- Start
- Mar 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of liquid metformin (Aspargo Labs) in type 2 diabetes mellitus (T2DM), sponsored by National Center for Cardiovascular Disease. Started Mar 2025; status: recruiting.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06932874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06932874.